Stepan Company (SCL) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
28 Apr, 2026Executive summary
Adjusted EBITDA for Q1 2026 was $49.6M, down 14% year-over-year, mainly due to lower surfactant earnings, production timing in Asia, competitive pressures in Mexico, severe weather in North America, and higher oleochemical costs.
Adjusted Net Income was $10.3M, a 47% decline year-over-year, primarily from lower surfactant earnings and higher interest expense related to the Pasadena, TX start-up.
Reported a net loss of $41.4M versus $19.7M income in prior year, driven by a $65.4M pre-tax restructuring charge.
Free cash flow improved 46% year-over-year to $14.0M, driven by working capital discipline, though one source notes negative free cash flow due to typical Q1 working capital needs.
Project Catalyst, an operational efficiency initiative, is on track to deliver $100M in pre-tax savings over two years, with ~60% expected in 2026.
Financial highlights
Net sales for Q1 2026 were $604.5M, up from $593.3M in Q1 2025, driven by higher selling prices and favorable currency translation.
Adjusted EBITDA declined 14–15% year-over-year, with surfactants down due to lower absorption and cost pressures, while polymers saw an 8% increase from margin recovery and growth in spray foam and commodity phthalic anhydride.
Adjusted Net Income excludes $51.2M after-tax restructuring charges, $0.5M deferred compensation expense, and $0.1M environmental remediation expense.
Reported net income was a loss of $41.4M, compared to a profit of $19.7M in Q1 2025, due to significant restructuring charges.
Adjusted earnings per diluted share was $0.45, down 46% from $0.84.
Outlook and guidance
FY2026 capital expenditures are guided at $105–115M, down from $122.5M in 2025.
Effective tax rate expected at 24–26% for 2026.
Project Catalyst expected to deliver $100M in pre-tax savings over two years, with ~60% realized in 2026.
Management expects full-year adjusted EBITDA growth, positive free cash flow, and continued balance sheet de-leveraging in 2026 despite market uncertainties.
Focus remains on growth in Crop Productivity, Oilfield, Tier 2/3 Surfactants, and North American Polymers.
Latest events from Stepan Company
- 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation28 Apr 2026 - EBITDA grew 6% in 2025; Project Catalyst to drive $100M savings, with H2 2026 margin recovery.SCL
Q4 202511 Apr 2026 - Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing25 Mar 2026 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 20242 Feb 2026 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 202417 Jan 2026 - Net income up 42% and EBITDA up 12% on strong surfactant and specialty growth.SCL
Q1 202524 Dec 2025 - Net income up 25% and adjusted EBITDA rose 4%, with Pasadena facility to boost 2025 growth.SCL
Q4 202423 Dec 2025 - Key votes include director elections, executive pay, auditor ratification, and equity plan expansion.SCL
Proxy Filing1 Dec 2025 - Strategic investments and innovation drive growth in key markets, with renewed segment momentum in 2024.SCL
16th Annual Midwest Ideas Conference23 Nov 2025